Insertion/deletion polymorphism of ACE gene in females with peripartum cardiomyopathy: A case-control study

Irfan Yaqoob, Nisar A. Tramboo, Irfan A. Bhat, Arshad Pandith, Jahangir R. Beig, Imran Hafeez, Aijaz A. Lone, Tariq R. Shah, Sumera Samreen

ARTICLE INFO

Article history:
Received 22 May 2016
Accepted 27 May 2017
Available online 1 June 2017

Keywords:
Peripartum cardiomyopathy
Heart failure
Angiotensin converting enzyme gene
Echocardiography

ABSTRACT

Background: The role of polymorphism of Angiotensin converting enzyme (ACE) gene and ACE activity in etiopathogenesis, prognosis, and many other clinical parameters in the various forms of the cardiovascular disease has been established to some degree of certainty. The pathophysiology of Peripartum cardiomyopathy (PPCM) remains an area of active research. The main aim of our study was to see pattern of ACE- Insertion/Deletion (I/D) allele in PPCM and its implications on left ventricular performance indices.

Methods: This single-center case-control study included 45 cases and 70 controls. The diagnosis of PPCM was established clinically and echocardiographically. ACE genotyping was done by polymerase chain reaction (PCR) method in all subjects.

Results: The II, ID, and DD genotype was present in 12, 18 and 11 of subjects with PPCM and 48, 19 and 3 of controls respectively. The odds ratio for ACE-II genotype in cases vs. controls was 0.253 (95% CI = 0.114-0.558; p = 0.007), for that of II genotype was 1.93 (95% CI = 0.86-4.3; p = 0.107) and for DD genotype was 7.225 (95% CI = 1.88-27.6; p = 0.0039). Overall frequency of D allele in cases was significantly higher than controls (odds = 4.25; 95% CI = 2.01-6.7; p = 0.0001). Moreover, ejection fraction, left ventricular volume and linear dimensions were worse in patients with DD genotype.

Conclusion: ACE DD genotype and overall frequency of D allele is significantly higher in patients with PPCM. Also, the presence of DD genotype is associated with worse systolic performance indices measured echocardiographically.

© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Peripartum cardiomyopathy (PPCM) has been traditionally defined as rare, acquired, idiopathic, non-genetic, non-familial and dilated cardiomyopathy that presents with heart failure secondary to left ventricular systolic dysfunction in last month of pregnancy or first five months after delivery, in the absence of any other cause of heart failure.1–5 Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that converts Angiotensin I to Angiotensin II which is a potent vasoconstrictor, stimulates adrenal cortex to release aldosterone which increases plasma volume, mediates cell growth and proliferation by stimulating various cytokines, growth factors and induces endothelial dysfunction by reducing nitric oxide bioavailability. These mechanisms emphasize the importance of angiotensin II in cardiovascular pathophysiology and motivate the exploration of the role of the renin-angiotensin-aldosterone system (RAAS) in cardiovascular pathology.6,7

The role of insertion/deletion (I/D) polymorphism of ACE gene and ACE activity in etiology, pathogenesis, prognosis, and other clinical implications in the various form of the cardiovascular disease has been established to some degree of certainty. ACE gene polymorphism in various specific cardiomyopathies like that of ischemic, idiopathic dilated, hypertrophic and alcoholic cardiomyopathy have been studied depicting the positive correlation between the frequency of D allele and development of specific cardiovascular pathophysiology. The fact that idiopathic dilated cardiomyopathy (IDCM), alcoholic cardiomyopathy and other forms of low ejection fraction state bear a phenotypic resemblance to that of PPCM, has prompted us to take on the study of the association of ACE gene I/D polymorphism in patients with PPCM.8

We for the first time tested the hypothesis that PPCM may be
associated with higher incidence of ACE-DD genotype and overall frequency of D allele and that the DD genotype in cases may be associated with the lower systolic performance of left ventricle.

2. Methods

2.1. Study design

This was a single centre hospital-based, Case-control study done in Kashmir (A state of north India) and carried out from August 2012 to March 2015.

2.2. Study population

CASES: The study population included 45 consecutive Kashmiri patients admitted to our hospital with PPCM diagnosed by clinical (Presentation of heart failure in last month of pregnancy or first 5 months postpartum) and echocardiographic (left ventricular ejection fraction <0.45 or M-mode fractional shortening <30% (or both) and end-diastolic dimension >2.7 cm/m²) criteria. Patients with a history of the pre-existing cardiac disease, hypertension (essential or pregnancy induced) or any structural heart disease inconsistent with PPCM on echocardiography and those with multiple gestations were excluded from the study. CONTROLS: A total number of controls were 70. Controls were healthy married normotensive, Kashmiri females, within first five months of puerperium with no history suggestive of cardiac disease, structurally and functionally normal heart (measured echocardiographically) and no history of pregnancy induced hypertension.

2.3. Consent and ethical issues.

An informed consent was obtained from each subject after explaining the study in detail. The study was cleared by the Institutional Ethics Committee.

2.4. Initial evaluation

Patient’s New York Heart Association (NYHA) functional class was assessed at first contact by thorough interview.13 This was followed by complete general physical and specific cardiovascular examination. Standard 12 lead ECG was recorded in all patients and Chest radiography was done in only 31 patients who had presented in the postpartum period in order to avoid radiation exposure to the fetus.

2.5. Echocardiography

A comprehensive echocardiographic examination of patients and controls was carried out using a commercially available cardiac ultrasound scanner equipped with 2.5 and 3.5 MHz transducers (Aloka, Prosound, SSD α=110, South Korea), by an experienced cardiologist. Each patient was examined in the left lateral decubitus and supine position by precoardial transthoracic two-dimensional targeted M-mode echocardiography with Doppler color flow mapping. Echocardiographic parameters that were recorded were systolic and diastolic left ventricular dimensions, fractional shortening, diastolic functions by transmitral flow velocities, left ventricular end diastolic volume, end systolic volume and ejection fraction by Simpson’s method and left atrial diameter. These measurements taken were strictly according to the joint guidelines by American Society of Echocardiography and European Association of Echocardiography.14 Measurements of left ventricular dimensions and function were determined by an average of ≥3 beats. Subjects were categorized as follows on the basis of echocardiographic parameters: Mild LV dysfunction, EF = 41–45, moderate LV dysfunction, EF = 31–40 and severe LV dysfunction, EF ≤ 30. Furthermore, subjects were classified on the basis of severity of LV dilatation as follows: Normal LV end diastolic volume =56–104 ml; Mild LV dilatation, LVEDV, 105–117 ml; Moderate LV dilatation, LVEDV, 118–130 ml; and Severe LV dilatation; LVEDV > 130.14

2.6. Extraction and amplification of genomic DNA

Blood samples were taken from both the groups after obtaining written informed consent. Five milliliters of peripheral blood was obtained from each subject in ethylenediaminetetraacetic acid (EDTA) containing vials (200 µl of 0.5 M, pH 8.0) and stored at −20°C until use. Deoxyribonucleic acid (DNA) extraction from blood sample was performed according to the manufacturer’s protocol for Qiagen DNA extraction kits (Qiagen, Hilden, NRW, Germany). DNA content was quantified by spectrophotometric absorption (Nanodrop Spectrophotometer, BioLab, Scoresby, VIC, Australia). Polymerase chain reaction (PCR) was performed using an iCycler Thermal Cycler (Bio-Rad, Hercules, CA, USA). Molecular detection of the ACE I/D polymorphism was performed by PCR amplification of 287-bp sequence of DNA of intron 16. The template DNA (0.5–10 µg) was used in a PCR under stringent conditions to avoid the possibility of false positives for ACE genotyping. The reactions were carried out with 10 pmol of each primer: Forward primer, 5’-CTG GAG ACC ACT CCC ATT TCT TCT-3’, and reverse primer, 5’-GAT GTG GCC ATC TTC GTC AGA T-3’, in a final volume of 25 µl containing 1.5 mM MgCl2, 25 mM KCl, 5 mM Tris-HCl (pH 8.4), 0.25 mM each of deoxyribonucleotide triphosphate (dNTP, Biotools, Spain) and 1 unit Taq polymerAASe (Biotools, Spain). Amplification was carried out in a DNA thermal cycler (Pamycycler thermocycler) for 30 cycles with denaturation extension at 72 0°C for 2 min. The PCR products were separated on a 2% agarose gel and DNA were visualized by ethidium bromide staining. The PCR product is a 490-bp fragment in the presence of the insertion (I) allele. Thus, each DNA sample revealed one of three possible patterns after electrophoresis: A 490-bp band (genotype I/I), a 190-bp band (genotype D/D), or both 490-bp and 190-bp bands (genotype I/D). Restriction fragments were visualized after ethidium bromide staining of the agarose gel with the use of an ultraviolet transilluminator (Fig. 1).

2.7. Collection and recording of data

All the patient data including demographic, clinical and diagnostic data as well as hospital outcome were recorded on a specially pre-designed patient record form.

Fig. 1. Direct visualization of ACE I/D PCR products, electrophoresed on 2% agarose gel, by ethidium bromide staining. A 490 base pair ACE I allele and 190 base pair ACE D allele is seen. Results from 8 patients are shown. II homozygote genotypes: Lane 6 and 8. DD homozygote: Lanes 3, 5 and 7. ID heterozygotes: Lane: 1 and 2. Control (D, H2O): 4
2.8. Statistical analysis

All continuous variables of study have been shown in terms of Mean ± SD and the categorical variables in terms of frequency and percentage. Continuous variables have been compared using T-test and Chi-square test has been used to analyze categorical variables. All the results obtained have been discussed on 5% level of significance with p value < 0.05 considered as significant. Also suitable statistical charts have been used to represent the data, SPSS version 20 was used for analysis.

3. Results

3.1. Patient characteristics

After excluding four patients (with two having associated pregnancy induced hypertension one patient had twin pregnancy and one patient had poor echocardiographic window that precluded the proper assessment), total of 45 patients who met the inclusion criteria, were enrolled in the study. Demographic characteristics of cases and controls are depicted in Table 1. There wasn’t significant difference in terms of age and parity between the two groups.

3.2. Clinical characteristics

NYHA class III was the most common presentation followed by class II and class IV respectively. Breathlessness was present in 91%, nocturnal cough in 51% and palpitations in 26% patients. Most patients had normal blood pressure at presentation (n: 33; 73%), 9 patients (20%) were in hypotension and 3 patients were in clinical shock. There was a significant difference in the mean heart rate between two groups. Chest radiograph was done only in patients presenting postpartum (n = 31) to avoid the radiation exposure to the fetus, out of whom 21 (65.6%) had CTR greater than 5.5.

3.3. Echocardiographic parameters

Baseline echocardiographic parameters of the cases and controls are depicted in Table 2. There was a significant difference in mean ejection fraction (EF), left ventricular systolic and diastolic indices between cases and controls. Total of 11 patients (24.4%) had normal left ventricular volume. Eleven cases (24%) had moderate to severe secondary mitral regurgitation (Fig. 2).

3.4. ACE genotype

The ACE genotype was determined in 45 patients with PPCM and compared with 70 controls. The results are shown in Table 3. When mean EF, mean of left ventricular end diastolic and end systolic diameters and volume of cases with II+ID genotype was compared with that of DD genotype, later had worse parameters but same was not statistically significant (Table 4).

Mean left atrial size didn’t differ much between the two groups.

4. Discussion

The main findings of our study were:

1. ACE-DD genotype was statistically significant in patients with PPCM
2. Overall frequency of D allele was significantly higher in cases
3. DD genotype was associated with worse systolic performance indices in terms of ejection fraction, LV end-systolic and end-diastolic dimensions and volumes.

The renin-angiotensin system (RAAS) plays a central role in cardiovascular homeostasis. Angiotensin is the key peptide of the RAAS and exerts its influence on the heart and blood vessels both through its hemodynamic effects (via its influence on after-load and pre-load and determining coronary vasoconstriction) and through its direct cellular effects (via its actions on cell proliferation). The discovery that ACE levels are under genetic control ushered in a new era of investigation; most studies focused on an insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene as a marker for a functional polymorphism. In 1990, Rigat and coworkers published an important report that provided the impetus to further study polymorphisms in this gene. They found a polymorphism involving the presence (insertion, I) or absence (deletion, D) of a 287-bp sequence of DNA in intron 16 of the gene. Mean ACE activity levels in DD carriers were approximately twice that found in II genotype individuals. Subjects with the ID genotype had intermediate levels indicating codominance. The I/D polymorphism accounted for approximately half (47%) of the observed variance in ACE levels in this study group. Later studies

| Table 1 Demographic and clinical characteristics. |
|-----------------------------------------------|
| **Cases**                                      | **Controls**                             |
| Age                                           |                                            |
| Mean (years) 31.8 ± 5.19                      | Mean (years) 31.48 ± 4.42                |
| Range (years) 22–42                           | Range (years) 24–40                      |
| Parity                                        | P = NS                                   |
| Mean 2.56 ± 1.27                              | Mean 2.14 ± 0.92                         |
| Range 1–6                                     | Range 1–5                                |
| Clinical characteristics of Cases             |                                            |
| NYHA Class                                    |                                            |
| II                                            | n = 13 (29%)                             |
| III                                           | n = 25 (55.5%)                           |
| IV                                            | n = 7 (15.5%)                            |
| Clinical Signs                                |                                            |
| Systolic BP (mmHg)                            |                                            |
| >90                                           | n = 9 (20%)                              |
| <90                                           | n = 3 (6.6%)                             |
| <90 with clinical signs of shock              | Controls = 83.8 ± 10.4                   |
| Mean Heart rate                               | P < 0.05                                |
| Periphered edema                              | Cases = 104.4 ± 16.5                     |
| Raised JVP                                    |                                            |
| n = 29 (64.4%)                                |                                        |
| Murmur                                        |                                            |
| n = 26 (57.7%)                                |                                        |
| Clinical S3                                   |                                            |
| n = 8 (17.8%)                                 |                                        |
| n = 19 (42.3%)                                |                                        |

NYHA = New York heart association; JVP = jugular venous; BP = Blood Pressure; ECG = Electrocardiogram; CTR = Cardiotoracic ratio.

* P value significant.
showed that the involvement of the I/D polymorphism is not limited to ACE levels in plasma, and is also detected in tissue ACE levels. 10,11

Although there is no reported study regarding ACE-gene I/D polymorphism in PPCM, various cardiovascular abnormalities bearing phenotypic resemblance to that of PPCM have shown a positive correlation with D allele and specific cardiomyopathy. In our study, we could establish a positive association between subjects with PPCM with DD genotype and D allele of ACE gene, which is in consistency with many other studies primarily involving cardiac muscle. Raynolds et al. determined the genotypes of individuals with end-stage heart failure due to either ischaemic dilated cardiomyopathy or idiopathic dilated cardiomyopathy and compared these to organ donors with normally functioning hearts. Compared with the DD frequency in the control population, the frequency of the ACE DD genotype was 48% higher in individuals with idiopathic dilated cardiomyopathy (p = 0.008) and 63% higher in subjects with ischaemic cardiomyopathy (p = 0.008), suggesting that an ACE gene variant may contribute to the pathogenesis of both types of cardiomyopathy. 12 Mahjoub et al. found a similar result in Tunisian population with diluted cardiomyopathy. They concluded that frequencies of the DD genotype and D allele were significantly higher in patients with dilated cardiomyopathy as compared with controls. 13 Another form of myocardial disease like hypertrophic cardiomyopathy and alcoholic cardiomyopathy has also been shown to have an association with DD genotype and with a higher frequency of D allele. 14–16 In our study, we could establish a positive association between DD genotype and D allele of ACE gene in subjects with PPCM which is in consistency with many other studies involving primarily cardiac muscle.

We also found that echocardiographically determined left ventricular systolic performance indices were affected by ACE I/D polymorphism. Mean LV-ejection fraction was lower and mean of LV linear dimension and volume was higher in cases with DD genotype when compared with combined mean of cases with ID and II genotype. Previous studies have almost consistently shown worse echocardiographic systolic performance indices (EF, LV dimensions, and volumes) as well as overall prognosis with DD genotype in other phenotypically similar cardiomyopathies. 17–19 Moreover, patients with DD genotype have shown to get maximum benefit from pharmacological ACE antagonism. 20 This observation may have implication on patients of PPCM as they are usually denied the beneficial effects of ACE inhibitors late in pregnancy owing to deleterious effects on the fetus.

Although exact etiology and pathogenesis of PPCM are an active area of research, our study may open the new dimensions in this area. Moreover, studies have conclusively shown that long-term inhibition of Renin-Angiotensin by various drugs started early in the course of the disease in other phenotypically similar forms of cardiomyopathy alters the natural course and promotes reverse remodeling of left ventricle, same benefit may, however, be denied

Table 2

| Cases | Controls | Controls |
|-------|----------|----------|
| n=9 | n=63 | 90% | 20% |
| n=27 | n=7 | 60% | 10% |
| n=5 | n=7 | 11% | 11% |
| n=4 | n=4 | 8,8% | 8,8% |
| n=21 | n=21 | 14,4% | 14,4% |
| n=11 | n=11 | 65,6% | 65,6% |

| Ejection Fraction | Mean | EF >45 | EF >40 | EF >30 |
|-------------------|------|--------|--------|--------|
| LV dimensions | LVEDD (mm) | Mean = 59.2 (70.4) | 47.4 (4.6) | P < 0.05 |< |
| LVEDV (ml) | Mean = 120 (26.24) | 105.7 (23.8) | P < 0.05 |< |

EF = ejection fraction; LVEDD = left ventricular end diastolic diameter; LVESD = left ventricular end systolic diameter; LV = left ventricle; Recommendations of report from American Society of Echocardiography’s in conjunction with European Association of Echocardiography, a branch of ESC. 1 Normal LV end diastolic volume; 56–104 ml, Mild LV dilatation LVEDD; 105–117 ml, Moderate LV dilatation LVEDD; 118–130 ml, Severe LV dilatation; LVEDV > 130. 14 EF was calculated by Simpson’s method.

Table 3

Comparison of ACE I/D genotype in cases vs. controls.

| Cases | Controls | Odds ratio | 95% CI | P value |
|-------|----------|------------|-------|---------|
| II 16 (35.5%) | 48 (68.5%) | 0.253 | 0.164–0.558 | 0.007 |
| ID 18 (40%) | 19 (27.1%) | 1.93 | 0.864–4.3 | 0.107 |
| DD 11 (24.4%) | 3 (4.3%) | 7.225 | 1.882–27.6 | 0.0039 |
| D 40 (44.4%) | 25 (17.9%) | 0.27 | 0.14–0.49 | 0.0001 |

Bold values represent significant p value.

Fig. 2. Line diagram showing the frequency of I/D polymorphism in cases vs. controls.
in this specific form of cardiomyopathy as inhibitors of Renin-Angiotensin system in late pregnancy (when pathophysiology of this disease entity usually starts) are absolutely contraindicated. The development of so-called “Pregnancy safe ACE inhibitor or ARB” may have a protective role, halt or reverse the disease progression in such cases.

Owing to the rarity of the disease, the number of patients in our study was relatively small, therefore results might be open to interpretation, a clear interrelation between genotypes and PPCM could nonetheless be seen. Further population-based, multicenter studies over longer periods involving multiple geographic regions and different ethnic groups should be done. Also, longitudinal follow-up studies where long-term prognosis and recovery of left ventricular functions in different genetic groups of ACE-gene need to be carried out.

5. Conclusion

This case-control study has demonstrated that the ACE DD genotype and overall frequency of D allele is significantly higher in patients with PPCM. Thus, the presence of D allele and DD genotype may predispose and may be an independent risk factor for the development of PPCM. Also presence of ACE-gene DD genotype in our study is associated with worse left ventricular function. Further studies, however, need to be undertaken with a larger number of patients taking region and ethnicity into account.

6. Study limitations

- The major limitation of this study is the small sample size owing to the low prevalence of PPCM in our community. This has resulted in wide confidence intervals and lower statistical power of the study.
- Moreover, our study comprised of the single ethnic population, the polymorphism of ACE genotype may vary in different regions of the world.
- We did not study the long term follow-up of these patients. Polymorphism of ACE gene may have implications on overall prognosis in PPCM. Longitudinal studies studying the death, hospitalisations for heart failure and recovery of LV functions in correlation with I/D polymorphism of ACE gene need to be put into perspective.

Declaration of interest

The authors have none to declare.

Acknowledgments

We acknowledge with warm thanks the cooperation of the patients and controls of this study as well as the SKIMS administration for funding this study.

References

1. Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971;44(6):1053–1061.
2. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: national heart, lung, and blood institute and office of rare diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283 (March [9]):1181–1188.
3. Shiva K, Fett J, ElKayam U. Peripartum cardiomyopathy. Lancet. 2006;368 (9536):687–693.
4. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(19):2388–2442.
5. Maron BJ, Towbin JA, Thiene G, et al. An American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113 (April [14]):1807–1816.
6. Erdos EG, Skidell RA. The angiotensin I converting enzyme. Lab Invest. 1978;38:345–348.
7. Carluccio M, Soccio M, De Caterina R. Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system. Eur J Clin Invest. 2001:31:476–488.
8. van Spaendonk-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121(May (20)):2169–2175.
9. Rigat B, Hubert C, Alhenc-Gelas F, Cambier P, Corvol P, Soubré F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346.
10. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Wittenberg JC. “ACE polymorphism”. Circ Res. 2006;98(May (9)):1123–1133.
11. Costerousse O, Allegriani J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993:290:33–40.
12. Raynolds Raynolds MV, Bristow MR, Bush EW, et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993;342(October (8879)):1085–1086.
13. Mihaylov S, Mehri S, Bousaada R, et al. Association of ACE I/D polymorphism in Tunisian patients with dilated cardiomyopathy. J Renin Angiotensin Aldosterone Syst. 2010;11(September (3)):187–191.
14. Marian AJ, Yu QT, Workman R, et al. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342(October (8879)):1085–1086.
15. Kawaguchi Hideaki. Angiotensin-converting enzyme and angiotensinogen gene polymorphism in hypertrophic cardiomyopathy. Exp Clin Cardiol. 2003;8 (3):155–159 Fall.
16. Fernández-Sola J, Nicolás JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med. 2002;137(September (5 Part 1)):321–326.
17. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387–1388.
18. Huang W, Xie C, Zhou H, Yang T, Sun M. Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. Eur J Heart Fail. 2004;6(January (1)):23–27.
19. Andersson B, Sylvén C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. Am Coll Cardiol. 1996;28(July (1)):162–167.
20. McNamara DM, Holubkov R, Postava L, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44(November (10)):2019–2026.